prednisone has been researched along with dasatinib in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beverloo, HB; Cornelissen, JJ; Deenik, W; Valk, PJ; van der Poel-van de Luytgaarde, SC; van Esser, JW; Wattel, MM | 1 |
| Hamerschlak, N; Kerbauy, FR; Mac-Donald Bley do Nascimento, C; Mauro Kutner, J; Ribeiro, AA; Rodrigues, M; Santos, FP | 1 |
| Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Biancon, G; Carniti, C; Cavanè, A; Corradini, P; Dugo, M; Magni, M; Paolizzi, C; Rizzitano, S | 1 |
| Jin, J; Li, XY; Meng, HT; Qian, JJ; Tong, HY; Wang, SS; Yang, M; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH | 1 |
| Aparicio, A; Araujo, JC; Boukovala, M; Corn, PG; Efstathiou, E; Hoang, A; Kim, J; Logothetis, CJ; Pagliaro, L; Spetsieris, N; Subudhi, SK; Tannir, NM; Troncoso, P; Tsikkinis, A; Tu, SM; Wang, J; Wang, X; Weldon, JA; Wen, S; Zurita, AJ | 1 |
| Advani, AS; Atallah, EL; Erba, HP; Gerds, AT; Jeyakumar, D; Liesveld, JL; Litzow, M; Moseley, A; O'Brien, SM; O'Dwyer, KM; Othus, M; Park, J; Sharon, E; Stone, RM; Wieduwilt, M; Wood, BL; Yaghmour, G | 1 |
| Feng, W; Hu, H; Hu, S; Huang, X; Jin, J; Kuang, Y; Le, J; Li, X; Lin, Y; Lu, Y; Mai, W; Meng, H; Ouyang, G; Qian, J; Qian, S; Shi, T; Tong, H; Wang, Y; Wei, J; Wu, G; Xie, M; Xu, G; Yang, C; Yang, M; Yao, G; Zhang, L; Zhu, HH; Zhu, W | 1 |
| Haddad, FG; Kourie, HR; Saleh, K | 1 |
1 review(s) available for prednisone and dasatinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for prednisone and dasatinib
| Article | Year |
|---|---|
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Random Allocation; Sunitinib; Treatment Outcome; Tumor Microenvironment | 2021 |
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction | 2023 |
8 other study(ies) available for prednisone and dasatinib
| Article | Year |
|---|---|
Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Cytarabine; Dasatinib; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; In Situ Hybridization, Fluorescence; Male; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neutropenia; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Remission Induction; Splenic Rupture; Thiazoles; Vincristine; Young Adult | 2009 |
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome | 2010 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Survival; Cyclophosphamide; Dasatinib; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Gene Expression; Gene Expression Profiling; Humans; Jurkat Cells; Lymphoma, T-Cell; Mice, Inbred NOD; Mice, SCID; Prednisone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-fyn; Receptors, Antigen, T-Cell; rhoA GTP-Binding Protein; Treatment Outcome; Up-Regulation; Vincristine | 2019 |
An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Dasatinib; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Retrospective Studies | 2020 |
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.
Topics: Aged; Aged, 80 and over; Dasatinib; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Treatment Outcome | 2023 |
Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors | 2023 |